Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Materialise NASDAQ: MTLS reported first-quarter 2026 revenue of EUR 66.3 million, which Chief Financial Officer Koen Berges said was stable year-over-year despite “significant foreign exchange headwinds,” primarily tied to a weaker U.S. dollar. Gross profit rose to EUR 37.9 million and gross margin expanded to 57.2%, helping drive improved profitability and positive free cash flow during the period.
Materialise NV (MTLS) Q1 2026 Earnings Call Transcript
Materialise receives a 'Buy' rating, driven by robust growth in its medical segment despite weakness in software and manufacturing. MTLS's medical segment boasts a 4-year CAGR of 16%, with management guiding for continued strong growth through FY2026. The company maintains a fortress balance sheet with €71m net cash and trades at a significant discount to sector peers on EV/Sales and EV/EBITDA.
Materialise is poised for a return to consistent growth and improving margins, led by Medical strength and stabilization of its Software business. The Manufacturing segment faces ongoing headwinds, but expansion into aerospace and defense could create a modest rebound over the next few years. The combination of a low valuation, consistent growth, and higher margins should lead the stock higher, which will be supported by a share buyback program.
Materialise NV (MTLS) Q4 2025 Earnings Call Transcript
Materialise (MTLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
JRVR, CALX, MTLS, AMX and NWFL have been added to the Zacks Rank #1 (Strong Buy) List on Dec. 18, 2025.
Materialise's Manufacturing segment continues to face headwinds, driven by exposure to areas like prototyping, automotive, and Europe. Materialise's Medical segment continues to perform well, and the Software segment appears set to rebound in coming quarters. Despite macro challenges, Materialise remains cash flow positive and has a strong net cash position.
Materialise is rated BUY with a $10 target, offering over 60% upside potential using a DCF with conservative assumptions. MTLS's Medical segment drives growth, offsetting industrial weakness; management focuses on mass personalization in healthcare and cost control. Industrial segment faces cyclical headwinds, but MTLS is shifting toward aerospace/defense and exiting less profitable operations to improve margins.
Materialise's Q2 results were weak due to European automotive headwinds and macro uncertainty. Materialise's Medical segment continues to thrive, and its Software business is nearly done transitioning to a recurring revenue model. Medical segment strength justifies a higher valuation, but the Manufacturing business must stabilize before the stock can meaningfully re-rate.
Materialise NV (NASDAQ:MTLS ) Q2 2025 Earnings Conference Call July 24, 2025 8:30 AM ET Company Participants Brigitte de Vet-Veithen - Chief Executive Officer Koen Berges - Chief Financial Officer Conference Call Participants Alexander Craeymeersch - Kepler Cheuvreux, Research Division Troy Donavon Jensen - Cantor Fitzgerald & Co., Research Division Harriet Fried - Unidentified Company Operator Good day, and thank you for standing by. Welcome to the Second Quarter 2025 Materialise NV Financial Results Conference Call.